Company
Technology
Team
Board of Directors
Management
Extended Management
Project Management
Partners & Advisors
Preclinical Research
Clinical Research
Strategic Investment
Investors
News
Company News
Scientific Publications
Contact
Company News
RocketVax has successfully completed another round of financing; The development of the second-generation COVID-19 vaccine moves forward
6 February 2023
READ MORE
Dr. Vladimir Cmiljanovic is a recipient of the 2023 Nikola Tesla Spirit Award
31 January 2023
READ MORE
Volker Thiel: "Wir planen noch besseren Corona-Impfschutz"
15 November 2022
READ MORE
RocketVax AG Announces New Milestones in the Development of Second-Generation COVID-19 Vaccines
23 September 2022
READ MORE
Burkhard Frey joins Rocketvax AG as Chief Commercial Officer
22 August 2022
READ MORE
SRF: Research on nasal corona vaccines raises hopes
22 August 2022
READ MORE
Dr. Milan Crnogorac joins RocketVax AG as Chief Technology Officer
9 August 2022
READ MORE
Bilanz: Important Milestone
28 June 2022
READ MORE
Finanz und Wirtschaft: Doubts about the market for corona boosters
24 June 2022
READ MORE
RocketVax SARS-CoV-2 Vaccine (RVX-sCPD9) Significantly Outperforms mRNA and Adenovirus Vector-Based Technologies in Animal Models
9 June 2022
READ MORE
Swiss vaccine candidates enter clinical trial phase
28 March 2022
READ MORE
New Swiss COVID-19 vaccination as a nasal spray
28 March 2022
READ MORE
RocketVax strengthens its technology portfolio and Covid-19 vaccine development through broad-based partnerships
16 March 2022
READ MORE
Serbian state institutions and media representatives have been reporting on the recipient of the Nikola Tesla Award, Dr. Vladimir Cmiljanovic
18 November 2021
READ MORE
Dr. Vladimir Cmiljanovic is the recipient of the 2021 Nikola Tesla Award for the achievements in the field of science
12 November 2021
READ MORE
LOAD MORE NEWS